Nevertheless, these findings are significant for high-risk MDS patients and the interplay between PI3K/Akt/mTOR and PI-PLCβ1 signaling pathways suggests potential combined therapeutic approaches to target disease progression. Here, AKT1 is linked to myelodysplastic syndrome.